Recently, the new crown specific drug s-217622 (its internal R & D number) of yanyeyi pharmaceutical in Japan has attracted great attention. It is reported that its cure rate has reached 100%. Is it really that divine?

In fact, the company started the phase 1 clinical trial of the new crown specific drug s-217622 as early as last July, mainly in Japan. Up to now, s-217622 has completed phase 2A clinical trial, and phase 2B clinical trial is still analyzing data. According to the information released by yanyeyi pharmaceutical, s-217622 has achieved good results.

o 1

How is the curative effect?

The clinical trial of s-217622 is mainly aimed at patients with mild / moderate symptoms. From the data of phase 2a, the nucleic acid test results of patients taking low-dose s-217622 were all negative on the sixth day (< 0.8 log10 (TCID50 / ml)), while the nucleic acid test results of patients taking high-dose s-217622 were also better than those taking placebo.

Phase 2B trial further expanded the object and observation scope, with 428 volunteers participating, mainly infected with Omicron virus. Yanyeyi pharmaceutical claimed that on the fourth day of taking s-217622, the proportion of positive patients was less than 10%, which was better than that in phase 2A compared with the control group. The symptoms of cough and runny nose were significantly improved. Relevant data will be released in the performance report of the first quarter of this year.

o 2

When will it be available?

Just last week (February 25), yanye pharmaceutical announced that it had submitted an application for production and sales license to Japan’s Ministry of health, labor and welfare. If approved, it will also become the third approved and the first new crown specific drug developed and produced by Japan. (molnupiravir of MSD and paxlovid of Pfizer have been conditionally approved to be put into use in the early stage)

In order to be put into the market as soon as possible, yanyeyi pharmaceutical has also made advance arrangements for the production of s-217622, which is expected to achieve a production capacity of 10 million people / year from April.

Recently, the new crown specific drug s-217622 (its internal R & D number) of yanyeyi pharmaceutical in Japan has attracted great attention. It is reported that its cure rate has reached 100%. Is it really that divine?

In fact, the company started the phase 1 clinical trial of the new crown specific drug s-217622 as early as last July, mainly in Japan. Up to now, s-217622 has completed phase 2A clinical trial, and phase 2B clinical trial is still analyzing data. According to the information released by yanyeyi pharmaceutical, s-217622 has achieved good results.

o 1

How is the curative effect?

The clinical trial of s-217622 is mainly aimed at patients with mild / moderate symptoms. From the data of phase 2a, the nucleic acid test results of patients taking low-dose s-217622 were all negative on the sixth day (< 0.8 log10 (TCID50 / ml)), while the nucleic acid test results of patients taking high-dose s-217622 were also better than those taking placebo.

Phase 2B trial further expanded the object and observation scope, with 428 volunteers participating, mainly infected with Omicron virus. Yanyeyi pharmaceutical claimed that on the fourth day of taking s-217622, the proportion of positive patients was less than 10%, which was better than that in phase 2A compared with the control group. The symptoms of cough and runny nose were significantly improved. Relevant data will be released in the performance report of the first quarter of this year.

o 2

When will it be available?

Just last week (February 25), yanye pharmaceutical announced that it had submitted an application for production and sales license to Japan’s Ministry of health, labor and welfare. If approved, it will also become the third approved and the first new crown specific drug developed and produced by Japan. (molnupiravir of MSD and paxlovid of Pfizer have been conditionally approved to be put into use in the early stage)

In order to be put into the market as soon as possible, yanyeyi pharmaceutical has also made advance arrangements for the production of s-217622, which is expected to achieve a production capacity of 10 million people / year from April.